Risk of CKD in Diabetic Patients With MAFLD

S

Sohag University

Status

Not yet enrolling

Conditions

Type 2 Diabetes

Treatments

Diagnostic Test: transient elastography (Fibroscan)

Study type

Observational

Funder types

Other

Identifiers

NCT06304844
Soh-Med-24-02-06MD

Details and patient eligibility

About

This cross-sectional study of 300 participants investigates the risk of chronic kidney disease (CKD) in individuals with metabolic dysfunction-associated fatty liver disease (MAFLD) and type 2 diabetes. By evaluating hepatic measurements and metabolic markers, the study aims to identify key risk factors for CKD in this population, contributing valuable insights to inform targeted interventions.

Full description

investigators plan to enroll 300 participants with type 2 DM to comprehensively investigate the risk of chronic kidney disease (CKD) in individuals diagnosed with metabolic dysfunction-associated fatty liver disease (MAFLD) and type 2 diabetes mellitus. In this study, the participant population will be grouped based on presence of MAFLD or not into 2 groups, then the group with MAFLD will be subdivided into subgroups based on the degree of hepatic involvement, considering both controlled attenuation parameter (CAP) values for steatosis and liver stiffness measurements for fibrosis via fibro scan device. This grouping strategy aims to categorize individuals into distinct cohorts, such as Low Hepatic Involvement and High Hepatic Involvement groups, facilitating a nuanced exploration of the association between hepatic conditions and the risk of chronic kidney disease (CKD) in the context of metabolic dysfunction-associated fatty liver disease (MAFLD) and type 2 diabetes mellitus.

Enrollment

300 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Type 2 diabetic patients
  • Willing and agreed to be included in the study.

Exclusion criteria

  • Type 1 diabetic patients or non-diabetic patients.
  • Patient with known glomerulonephritis.
  • Patient with diagnosis of or clinical features that are suspicious for another systemic disease that commonly causes kidney disease (e.g., connective tissue disorders, HIV).
  • Patient with evidence of alternative kidney disease like (Documented obstructive uropathy, etc.)
  • Patient with history of kidney transplantation.
  • Patient with end stage renal disease or on dialysis.
  • Patients with active malignancy.
  • Individuals with a history of hepatitis B surface antigen or hepatitis C antibody positivity.
  • history of excessive alcohol consumption (⩾30 g/day in men and ⩾20 g/day in women)
  • Decompensated liver cirrhosis.

Trial design

300 participants in 3 patient groups

diabetic without MAFLD
Description:
patients with type 2 DM but has no evidence of MAFLD
diabetic with MAFLD (high hepatic involvement)
Description:
patients with type 2 DM and have evidence of MAFLD (according to abdominal ultrasonography) and have high controlled attenuation parameter and liver stiffness measurement in Fibroscan
Treatment:
Diagnostic Test: transient elastography (Fibroscan)
diabetic with MAFLD (low hepatic involvement)
Description:
patients with type 2 DM and have evidence of MAFLD (according to abdominal ultrasonography) and have low controlled attenuation parameter and liver stffiness measurement in Fibroscan
Treatment:
Diagnostic Test: transient elastography (Fibroscan)

Trial contacts and locations

0

Loading...

Central trial contact

Ahmed Ismail, ass. lecturer

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems